357 related articles for article (PubMed ID: 15900600)
1. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
[TBL] [Abstract][Full Text] [Related]
2. The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Spurdle AB; Antoniou AC; Kelemen L; Holland H; Peock S; Cook MR; Smith PL; Greene MH; Simard J; Plourde M; Southey MC; Godwin AK; Beck J; Miron A; Daly MB; Santella RM; Hopper JL; John EM; Andrulis IL; Durocher F; Struewing JP; Easton DF; Chenevix-Trench G; ; ; ; ; ;
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):76-9. PubMed ID: 16434590
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers.
Kadouri L; Kote-Jarai Z; Easton DF; Hubert A; Hamoudi R; Glaser B; Abeliovich D; Peretz T; Eeles RA
Int J Cancer; 2004 Jan; 108(3):399-403. PubMed ID: 14648706
[TBL] [Abstract][Full Text] [Related]
4. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
Colilla S; Kantoff PW; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Garber JE; Lynch HT; Brown M; Weber BL; Rebbeck TR
Carcinogenesis; 2006 Mar; 27(3):599-605. PubMed ID: 16244359
[TBL] [Abstract][Full Text] [Related]
5. The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.
Montgomery KG; Chang JH; Gertig DM; Dite GS; McCredie MR; Giles GG; Southey MC; Hopper JL; Campbell IG
Breast Cancer Res; 2005; 7(3):R353-6. PubMed ID: 15987430
[TBL] [Abstract][Full Text] [Related]
6. The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development.
Kleibl Z; Havranek O; Kormunda S; Novotny J; Foretova L; Machackova E; Soukupova J; Janatova M; Tavandzis S; Pohlreich P
J Cancer Res Clin Oncol; 2011 Feb; 137(2):331-8. PubMed ID: 20422428
[TBL] [Abstract][Full Text] [Related]
7. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
Rebbeck TR; Wang Y; Kantoff PW; Krithivas K; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Brunet JS; Vesprini D; Garber JE; Lynch HT; Weber BL; Brown M
Cancer Res; 2001 Jul; 61(14):5420-4. PubMed ID: 11454686
[TBL] [Abstract][Full Text] [Related]
8. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
[TBL] [Abstract][Full Text] [Related]
9. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Spurdle AB; Antoniou AC; Duffy DL; Pandeya N; Kelemen L; Chen X; Peock S; Cook MR; Smith PL; Purdie DM; Newman B; Dite GS; Apicella C; Southey MC; Giles GG; Hopper JL; Chenevix-Trench G; Easton DF;
Breast Cancer Res; 2005; 7(2):R176-83. PubMed ID: 15743497
[TBL] [Abstract][Full Text] [Related]
10. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
Dagan E; Friedman E; Paperna T; Carmi N; Gershoni-Baruch R
Eur J Hum Genet; 2002 Nov; 10(11):724-8. PubMed ID: 12404104
[TBL] [Abstract][Full Text] [Related]
13. Polymorphic repeat length in the AIB1 gene and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis of observational studies.
Bianco A; Quaresima B; Pileggi C; Faniello MC; De Lorenzo C; Costanzo F; Pavia M
PLoS One; 2013; 8(3):e57781. PubMed ID: 23483928
[TBL] [Abstract][Full Text] [Related]
14. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
15. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
[TBL] [Abstract][Full Text] [Related]
16. Polyglutamine repeat length in the NCOA3 does not affect risk in familial breast cancer.
Wilkening S; Burwinkel B; Grzybowska E; Klaes R; Pamula J; Pekala W; Zientek H; Hemminki K; Försti A
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):291-2. PubMed ID: 15668512
[No Abstract] [Full Text] [Related]
17. Rapid detection of CAA/CAG repeat polymorphism in the AIB1 gene using DHPLC.
Kleibl Z; Havranek O; Prokopcova J
J Biochem Biophys Methods; 2007 Apr; 70(3):511-3. PubMed ID: 17234271
[TBL] [Abstract][Full Text] [Related]
18. The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Kaufman B; Laitman Y; Ziv E; Hamann U; Torres D; Lahad EL; Beeri R; Renbaum P; Jakubowska A; Lubinski J; Huzarski T; Tołoczko-Grabarek A; Jaworska K; Durda K; Sprudle AB; Chenevix-Trench G; Simard J; Easton DF; Antonis A; Szabo C; Friedman E
Breast Cancer Res Treat; 2011 Apr; 126(2):521-7. PubMed ID: 20798986
[TBL] [Abstract][Full Text] [Related]
19. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
Wang-Gohrke S; Weikel W; Risch H; Vesprini D; Abrahamson J; Lerman C; Godwin A; Moslehi R; Olipade O; Brunet JS; Stickeler E; Kieback DG; Kreienberg R; Weber B; Narod SA; Runnebaum IB
Br J Cancer; 1999 Sep; 81(1):179-83. PubMed ID: 10487631
[TBL] [Abstract][Full Text] [Related]
20. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
